Antiretroviral therapy in adults.
暂无分享,去创建一个
[1] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[2] J. Nielsen,et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. , 1994, JAMA.
[3] M. Uhlén,et al. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. , 1994, The Journal of infectious diseases.
[4] W. Freimuth. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. , 1996, Advances in experimental medicine and biology.
[5] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[6] M. Hirsch,et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. , 1990, The Journal of infectious diseases.
[7] P. Furth,et al. Nail pigmentation changes associated with azidothymidine (zidovudine). , 1987, Annals of internal medicine.
[8] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[9] D. Cooper,et al. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia , 1990 .
[10] D. Jeffries,et al. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. , 1989, The Journal of infection.
[11] A. Lazzarin,et al. Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV‐related thrombocytopenia , 1993, AIDS.
[12] S D Kemp,et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.
[13] M. Wulfsohn,et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome , 1990 .
[14] J. Cohen,et al. Acetaminophen does not impair clearance of zidovudine. , 1991, Annals of internal medicine.
[15] B. Larder,et al. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates , 1993, Antimicrobial Agents and Chemotherapy.
[16] B. Efron,et al. Didanosine Resistance in HIV-infected Patients Switched from Zidovudine to Didanosine Monotherapy , 1994, Annals of Internal Medicine.
[17] J. Lange,et al. Treatment of HIV Infection , 1996, Drug safety.
[18] D. Richman,et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. , 1990, The New England journal of medicine.
[19] J. Montaner,et al. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.
[20] J. Phair,et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. , 1994, JAMA.
[21] J. Barrish,et al. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor , 1995, Journal of virology.
[22] O. Paltiel,et al. Clinical correlates of subnormal vitamin B12 levels in patients infected with the human immunodeficiency virus , 1995, American journal of hematology.
[23] J. Veenstra,et al. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. , 1995, The Journal of infectious diseases.
[24] D. McCluskey. The medical management of AIDS , 1989, The Lancet.
[25] Robert T. Schooley,et al. Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex , 1989 .
[26] J. Fitzgibbon,et al. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation. , 1993, The New England journal of medicine.
[27] R. Schooley,et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. , 1989, JAMA.
[28] D. Kuritzkes,et al. Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .
[29] M. Falguera,et al. Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine , 1995, European journal of haematology.
[30] J. Sommadossi. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues. , 1995, The Journal of infectious diseases.
[31] S D Kemp,et al. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.
[32] Anne M Johnson,et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine , 1994 .
[33] J. Gatell,et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter , 1993 .
[34] P. Klenerman,et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. , 1994, The Journal of infectious diseases.
[35] T. Poynard,et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients , 1995, The Lancet.
[36] M. Dalakas,et al. Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.
[37] V. Herbert,et al. Synergy of inhibition of DNA synthesis in human bone marrow by azidothymidine plus deficiency of folate and/or vitamin B12? , 1990, American journal of hematology.
[38] S. Larson,et al. Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease , 1988, Annals of neurology.
[39] B. Gazzard,et al. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. , 1993, AIDS.
[40] D. Katzenstein,et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.
[41] W. Guerra. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .
[42] M. Fischl,et al. Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy , 1993, Annals of Internal Medicine.
[43] J. Phair,et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. , 1995, The New England journal of medicine.
[44] T. Merigan,et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. , 1992, The New England journal of medicine.
[45] Robert Schooley,et al. CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.
[46] J. Phair,et al. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). , 1994, Journal of acquired immune deficiency syndromes.
[47] Update: acquired immunodeficiency syndrome--United States. , 1986, MMWR. Morbidity and mortality weekly report.
[48] M. Saag,et al. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? , 1994, Infectious agents and disease.
[49] Paul Kellam,et al. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro , 1993, Nature.
[50] H. Burger,et al. Safety and activity of saquinavir in HIV infection , 1995, The Lancet.
[51] P Bacchetti,et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. , 1991, BMJ.
[52] M A Fischl,et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[53] M. Dudley. Clinical pharmacokinetics of nucleoside antiretroviral agents. , 1995, The Journal of infectious diseases.
[54] Ann Marie Swart,et al. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.
[55] J. Sninsky,et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.
[56] S. Safrin,et al. Drug interactions and toxicities in patients with AIDS , 1992 .
[57] R. Gelber,et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.
[58] A. James. Fat-soluble vitamins , 1995, The Lancet.
[59] E. Clercq. New Developments in the Chemotherapy of Lentivirus (Human Immunodeficiency Virus) Infections: Sensitivity/Resistance of HIV‐1 to Non‐nucleoside HIV‐1‐specific Inhibitors a , 1994 .
[60] G L Drusano,et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. , 1992, The New England journal of medicine.
[61] S. Hammer,et al. Zidovudine: Five Years Later , 1992, Annals of Internal Medicine.
[62] T Creagh-Kirk,et al. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. , 1988, JAMA.
[63] Douglas D. Richman,et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial , 1990 .
[64] P. Volberding,et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. , 1994, The New England journal of medicine.
[65] C. Hendrix,et al. PROBENECID AND ZIDOVUDINE METABOLISM , 1989, The Lancet.
[66] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[67] J. Phair,et al. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. , 1993, Journal of acquired immune deficiency syndromes.
[68] A. Cross,et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. , 1995, The Journal of infectious diseases.
[69] Update: AIDS among women--United States, 1994. , 1995, MMWR. Morbidity and mortality weekly report.